Osivax announces Last Subject Last Visit completed in Phase 2a Clinical Trial of OVX836 Universal Influenza Vaccine Candidate — Full immunogenicity and safety results expected for early 2021 –Lyon, France – September 10, 2020 –Osivax announced today that the Last Subject’s Last Visit (LSLV) occurred in the Phase 2a clinical trial of OVX836 universal Influenza …
Archives de la catégorie : Press
Osivax Receives Over EUR 30M in Public Funding to Support Development of Universal Coronavirus & Influenza Vaccines
Osivax Receives Over EUR 30M in Public Funding to Support Development of Universal Coronavirus & Influenza Vaccines — Company Secures EUR 17.5M from European Innovation Council and EUR 15.1M from Bpifrance as part of PSCP Covid-19 —Lyon, France – July 08, 2020 – Osivax announced today that it has received over EUR 30M in public funding from …
OSIVAX Announces Completion of Enrolment in its Phase 2a Clinical Trial of OVX836 Universal Influenza Vaccine Candidate
OSIVAX Announces Completion of Enrolment in its Phase 2a Clinical Trial of OVX836 Universal Influenza Vaccine Candidate — Top line results expected by the first quarter of 2021 —Lyon, France – April 09, 2020 – OSIVAX, a clinical stage biopharmaceutical company currently focusing on the development of a universal influenza vaccine candidate, announced today that it completed …
Osivax Announces First Volunteers Enrolled in Phase 2a clinical trial of OVX836 Universal Influenza Vaccine Candidate
Osivax Announces First Volunteers Enrolled in Phase 2a clinical trial of OVX836 Universal Influenza Vaccine Candidate — Phase 2a clinical trial on 300 healthy volunteers run under US IND —Lyon, France – January 21, 2020 – OSIVAX, a clinical stage biopharmaceutical company currently focused on the development of a universal influenza vaccine candidate, enrolled the first participant in …
Osivax Enters Agreement with U.S. National Institutes of Health to Test Universal Flu Vaccine Candidate
Osivax Enters Agreement with U.S. National Institutes of Health to Test Universal Flu Vaccine Candidate Lyon, France – December 5, 2019 – Osivax announced today that it has entered into an agreement with the United States’ National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to further advance the development …
Osivax Extends Executive Team to Strengthen Corporate Expansion and Accelerate the Development of Universal Flu Vaccine Candidate
Osivax Extends Executive Team to Strengthen Corporate Expansion and Accelerate the Development of Universal Flu Vaccine Candidate— Linda Lebon joins as Chief Regulatory Officer —— Florian Sourd joins as VP Finance — Lyon, France – October 30th, 2019 – Osivax announced today the appointment of Linda Lebon as Chief Regulatory Officer and Florian Sourd as VP …
Osivax Announces Last Participant Last Visit in its Phase 1 Clinical Trial of OVX836 Universal Influenza Vaccine Candidate
Osivax Announces Last Participant Last Visit in its Phase 1 Clinical Trial of OVX836 Universal Influenza Vaccine Candidate– Full safety and immunogenicity results expected for end 2019 — Lyon, France – September 26th, 2019 – Osivax announced today that all participants have completed their final visit in the first-in-human clinical trial of OVX836 universal Influenza vaccine …
Osivax secures EUR 8 Million of Financing through a Series A Round
Osivax Secures EUR 8 Million of Financing through a Series A Round to Develop Novel Universal Flu Vaccines and Expand oligoDOM® Technology Platform — Company to establish new subsidiary office in Liege, Belgium — Lyon, France – July 10, 2019 – Osivax announced today that it has secured EUR 8 million of financing through a Series …
Continuer la lecture « Osivax secures EUR 8 Million of Financing through a Series A Round »
Osivax appoints Dr. Paul Willems as Chief Medical Officer
Paul Willems’ appointment will strengthen Osivax’s capacities to design and implement an ambitious and impactful clinical development plan for its vaccines pipeline and especially the “universal” flu vaccine program Lyon, France – January 31st, 2019 – Osivax, a clinical stage biopharmaceutical company currently focused on the development of a breakthrough “universal” influenza vaccine program, announced today …
Continuer la lecture « Osivax appoints Dr. Paul Willems as Chief Medical Officer »
Approval of Osivax’ First in Human Clinical Trial for its Universal Influenza Vaccine Candidate
Osivax announces that the Belgian health authority approved the initiation of a first-in-human clinical trial evaluating the safety and immunogenicity of OVX836 in healthy volunteers Lyon, France – June 4, 2018 – Osivax, a clinical stage biopharmaceutical company currently focused on the development of a universal influenza vaccine candidate, announced today that the Belgian health authority …